Chinese Rheumatism Biobank Study Tracking Organ Damage in Systemic Lupus Erythematosus SLE Patients

What this Trial Is About

Systemic lupus erythematosus SLE is a complex autoimmune disease that causes damage to multiple organs over time. This research aims to understand how major organ damage develops in SLE patients by closely tracking their changes before and after organ damage occurs. The study focuses on the most common serious complications like lupus nephritis, thrombocytopenia, and the rarer pulmonary arterial hypertension, which greatly affect patients long-term health and quality of life. Participants will be observed as they receive treatments including antimalarial drugs with or without oral glucocorticosteroids. The glucocorticosteroid dose will be tapered over several weeks, while hydroxychloroquine will be given at initial and maintenance doses. The study collects detailed clinical and laboratory data to analyze the connection between molecular changes and organ damage progression. Research continues through various time points including up to 60 months for major organ involvement and 24 weeks for disease activity monitoring. During the trial, participants undergo regular clinical assessments to monitor disease activity and organ function. Researchers measure the occurrence of major organ involvement over five years and track disease activity and remission status within the first 24 weeks. This ongoing observation helps identify early warning signs and provides important data for improving future prediction models. The study is sponsored by the Chinese SLE Treatment And Research Group and runs until April 2033, allowing for comprehensive long-term follow-up.

Chinese Rheumatism Biobank(CRB)